

3. With respect to ISS mediated shift of the immune response toward a Th1 phenotype to suppress the Th2 immune phenotype, references include: page 5, lines 5-15; page 6, line 22- page 7, line 5; page 34, line 15 through page 36, line 24; and Examples IV, V and VII.

4. With respect to administration of ISS with separately delivered antigen, references include: page 6, lines 18-21("With co-administration of antigen or a recombinant expression vector encoding antigen, the naked gene expression vectors of the invention serve as adjuvants to enhance the immune response of a host to an antigen."); page 37, lines 1-11.

Applicants apologize for any confusion these errors may have caused. If the Examiner has any questions or comments in regard to this Correction to Preliminary Amendment, he or she is invited to contact the undersigned.

CONCLUSION

Applicants submit that the application is now in condition for allowance. If the Examiner has any questions concerning this Amendment, or believes discussion concerning the application would advance prosecution, he or she is invited to contact the undersigned.

Dated:

8-20-99

Respectfully submitted,



Stacy L. Taylor
Registration No. 34,842

FOLEY & LARDNER
Attorneys at Law
402 West Broadway, Suite 2300
San Diego, CA 92101-3542

Telephone: (619) 234-6655
Facsimile: (619) 234-3510